Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Zhonghua Liu Xing Bing Xue Za Zhi ; 44(6): 862-867, 2023 Jun 10.
Article in Chinese | MEDLINE | ID: mdl-37380405

ABSTRACT

Objective: To investigate the associations between the numbers of healthy lifestyles and overweight/obesity and abdominal obesity in adult twins in Shanghai. Methods: Based on the Shanghai Twin Registry System Phase Ⅱ survey data in 2017-2018, a case-control study was conducted to analyze the association between healthy lifestyles and obesity and further adjusted for confounders by a co-twin control study. Results: A total of 7 864 adult twins (3 932 pairs) were included. In the co-twin case-control analysis for monozygotic twins, compared with participants with 0 to 2 healthy lifestyles, those with 3 and 4 to 5 healthy lifestyles had a 49% (OR=0.51, 95%CI: 0.28-0.93) and 70% (OR=0.30, 95%CI: 0.13-0.69) lower risk of overweight/obesity, respectively, and a 17% (OR=0.83, 95%CI: 0.44-1.57) and 66% (OR=0.34, 95%CI: 0.14-0.80) lower risk of abdominal obesity, respectively. For each additional healthy lifestyle, the risk of developing overweight/obesity was reduced by 41% (OR=0.59, 95%CI: 0.42-0.85), and the risk of developing abdominal obesity was reduced by 37% (OR=0.63, 95%CI: 0.44-0.90). Conclusion: An increasing number of healthy lifestyles was associated with a marked decreased risk for both overweight/obesity and abdominal obesity.


Subject(s)
Obesity, Abdominal , Overweight , Adult , Humans , Case-Control Studies , China/epidemiology , Healthy Lifestyle , Obesity/epidemiology , Obesity, Abdominal/epidemiology , Overweight/epidemiology , Twins, Monozygotic
2.
Zhonghua Nei Ke Za Zhi ; 62(4): 356-362, 2023 Apr 01.
Article in Chinese | MEDLINE | ID: mdl-37032129

ABSTRACT

Standardisation and harmonisation of the detection of autoantibodies is important for the clinical application of autoantibodies. However, achieving complete standardisation is difficult and involves several challenges due to the complexity and particularity of autoantibody detection. Harmonisation is feasible and valued, but it involves all aspects and processes of autoantibody detection. Based on the consensus and practice of the clinical application of autoantibody detection in recent years, we discuss harmonisation in this review.


Subject(s)
Autoantibodies , Humans , Reference Standards
3.
Zhonghua Xue Ye Xue Za Zhi ; 44(1): 38-42, 2023 Jan 14.
Article in Chinese | MEDLINE | ID: mdl-36987721

ABSTRACT

Objective: To evaluate the clinical effects of low- and intermediate-dose factor Ⅷ (F Ⅷ) prophylaxis in Chinese adult patients with severe hemophilia A. Methods: Thirty adult patients with severe hemophilia A who received low- (n=20) /intermediate-dose (n=10) F Ⅷ prophylaxis at Nanjing Drum Tower Hospital affiliated with Nanjing University Medical College were included in the study. The annual bleeding rate (ABR), annual joint bleeding rate (AJBR), number of target joints, functional independence score of hemophilia (FISH), quality of life score, and health status score (SF-36) before and after preventive treatment were retrospectively analyzed and compared. Results: The median follow-up was 48 months. Compared with on-demand treatment, low- and intermediate-dose prophylaxis significantly reduced ABR, AJBR, and the number of target joints (P<0.05) ; the improvement in the intermediate-dose prophylaxis group was better than that in the low-dose prophylaxis group (P<0.05). Compared with on-demand treatment, the FISH score, quality of life score, and SF-36 score significantly improved in both groups (P<0.05), but there was no significant difference between the two groups (P>0.05) . Conclusion: In Chinese adults with severe hemophilia A, low- and intermediate-dose prophylaxis can significantly reduce bleeding frequency, delay the progression of joint lesions, and improve the quality of life of patients as compared with on-demand treatment. The improvement in clinical bleeding was better with intermediate-dose prophylaxis than low-dose prophylaxis.


Subject(s)
Hemophilia A , Humans , Hemophilia A/drug therapy , Factor VIII/therapeutic use , Quality of Life , Retrospective Studies , Hemarthrosis/drug therapy , Hemarthrosis/prevention & control , Hemorrhage/drug therapy
4.
Eur Rev Med Pharmacol Sci ; 24(17): 8918-8930, 2020 09.
Article in English | MEDLINE | ID: mdl-32964982

ABSTRACT

OBJECTIVE: Given that FK506 binding protein 51 (FKBP51) is upregulated in multiple cancers, we designed the present study to characterize its role as well as underlying regulatory mechanisms in glioma in the presence and absence of the chemotherapeutic carmustine (BCNU). MATERIALS AND METHODS: Through lentiviral overexpression and shRNA knockdown of FKBP51, we examined the effects on BT325 glioma cell proliferation, migration and invasion using quantitative reverse transcription PCR (qRT-PCR), CCK-8 assay, flow cytometry, and transwell assay. RESULTS: The upregulation of FKBP51 resulted in significantly decreased BT325 cell proliferation and cell viability, cell cycle arrest, reduced BCNU chemosensitivity and AKT pathway inactivation. However, FKBP51-overexpressed BT325 cells showed enhanced migration and invasion, which was supported by corresponding increase in phosphorylated IKKα (p-IKKα), MMP-2, and MMP-9 levels, as well as increased NF-κB p65 nuclear translocation. By contrast, FKBP51-suppressed BT325 cells showed excessive proliferation and BCNU resistance due to increased p-AKT activation and attenuated migration and invasion. CONCLUSIONS: We demonstrated that the effects of FKBP51 on BT325 glioma cell proliferation, migration, invasion and BCNU chemosensitization are modulated via the AKT and NF-κB pathways. Furthermore, our findings suggest the potential of FKBP51 as a prognostic glioma biomarker and an indicator of patient response to chemotherapy.


Subject(s)
Biomarkers, Tumor/metabolism , Glioma/metabolism , Tacrolimus Binding Proteins/metabolism , Antineoplastic Agents, Alkylating/pharmacology , Biomarkers, Tumor/genetics , Carmustine/pharmacology , Cell Movement/drug effects , Cell Proliferation/drug effects , Glioma/drug therapy , Glioma/pathology , Humans , Tacrolimus Binding Proteins/genetics , Tumor Cells, Cultured
6.
Article in Chinese | MEDLINE | ID: mdl-29365382

ABSTRACT

Objective: To evaluate the efficacy of systemic glucocorticoid (steroid) combined with high dose inhaled steroid in the treatment of children with acute laryngitis. Methods: A total of 78 children with acute laryngitis were randomly divided into study group(n=40) and control group(n=38) between November 2016 and April 2017. In addition to routine treatment of anti infection and symptomatic treatment, Dexamethasone injection(0.3-0.5 mg/kg, 1-3 d, according to the patient's condition) was provided to each group. In addition to the treatment mentioned above, the study group were assigned to receive 1.0 mg Budesonide suspension for inhalation, oxygen-driven atomizing inhalation, every/30 minutes, 2 times in a row, after that every 12 hours. The improvement of inspiratory dyspnea, hoarseness, barking cough and wheezing of both groups was evaluated at 30 min, 1 h, 2 h, 6 h, 12 h, 24 h and 72 h after treatment.Sigmaplot 11.5 software was used to analyze the data. Results: No significant difference was detected in terms of inspiratory dyspnea, hoarseness, barking cough or stridor score before treatment between the two groups(P>0.05). Compared with those before treatment, symptoms of inspiratory dyspnea, hoarseness, barking cough and stridor score of both groups improved markedly at 12 h and 24 h after treatment(P<0.05). While there was no significant difference regarding inspiratory dyspnea, hoarseness, barking cough or stridor score at each time point after treatment between the two groups(P>0.05). The effective rate was 92.50% and 92.11% in study group and control group, respectively, and no significant difference was noted (P>0.05). Conclusion: Compared with single systemic glucocorticoid, systemic glucocorticoids combined with inhaled steroid possessed similar efficacy in treating acute laryngitis and relieving laryngeal obstruction of children.


Subject(s)
Budesonide/therapeutic use , Dexamethasone/therapeutic use , Glucocorticoids/therapeutic use , Laryngitis/drug therapy , Acute Disease , Administration, Inhalation , Budesonide/administration & dosage , Child , Cough/drug therapy , Dexamethasone/administration & dosage , Drug Administration Schedule , Dyspnea/drug therapy , Glucocorticoids/administration & dosage , Hoarseness/drug therapy , Humans , Nebulizers and Vaporizers , Respiratory Sounds/drug effects
7.
Zhonghua Xue Ye Xue Za Zhi ; 37(11): 966-970, 2016 Nov 14.
Article in Chinese | MEDLINE | ID: mdl-27995882

ABSTRACT

Objective: To investigate the molecular etiology of protein C (PC) deficiency. Methods: Routine diagnosis and genetic analysis were performed on four probands with PC deficiency. Results: ①Case 1, female, 40 years old, diagnosed of deep vein thrombosis in left lower limb. PC activity (PC∶C) was 48%, PS activity (PS∶C) was 26.3%, AT activity (AT∶C) was 75.6%. Genetic analysis discovered heterozygous mutation C5156T on promoter of PC gene, together with heterozygous mutation A6578T on Exon2 of PC gene. After anticoagulant, thrombolysis and filter implantation therapies, the patient went home with improvement. ②Case 2, female, 32 years old, diagnosed of deep vein thrombosis in both lower limb, ischemia in both lower and upper limb, and skin infection in both lower limb. PC∶C 27%, PS∶C 22.9%, AT∶C 86.7%. Genetic analysis identified heterozygous mutation C5156T, together with heterozygous mutation A5045T on promoter of PC gene. After anticoagulant and anti-infection therapy, the patient died of respiratory failure, septic shock and DIC. ③Case 3, female, 28 years old, diagnosed of vein thrombosis in right iliac and femoral vein. PC∶C 58%, PS∶C 57.3% , AT∶C 80.8%. Genetic analysis disclosed heterozygous mutation C4867T on promoter of PC gene, AGA 12702-12704del or 12705-12707del on Exon7, the latter one lead to Arg192 or 193del. Heterozygous mutation G15240A on Exon9 was also found. After anticoagulant, thrombolysis and filter implantation therapies, the patient went home with improvement. ④Case 4, male, 30 years old, diagnosed of vein thrombosis in right iliac and femoral vein. PC∶C 50%, PS∶C 75.0%, AT∶C 89.1%. Genetic analysis found homozygous mutation C4867T and G4880A on promoter of PC gene, heterozygous mutation A5045T on promoter and heterozygous mutation T6589C on Exon2. After anticoagulant, thrombolysis and filter implantation therapies, the patient went home with improvement. ⑤ Polymorphism analysis revealed that heterozygous mutation C4867T, homozygous mutation G4880A, and heterozygous mutation C5156T were polymorphism sites of PC gene. Conclusions: Polymorphism sites (G4880A, C4867T, C5156T), missense mutation A5045T, A6578T, G15240A, and deletion mutation AGA12702-12704del, 12705-12707del may be related to deficiency of PC. Missense mutation A5045T, A6578T, G15240A, and deletion mutation AGA12702-12704, 12705-12707del were first reported worldwide.


Subject(s)
Heterozygote , Mutation, Missense , Protein C Deficiency/genetics , Protein C/genetics , Venous Thrombosis/genetics , Anticoagulants , Blood Coagulation Tests , Female , Genetic Testing , Homozygote , Humans , Male , Polymorphism, Genetic , Promoter Regions, Genetic/genetics , Protein C Deficiency/diagnosis
8.
Genet Mol Res ; 10(4): 4147-57, 2011 Oct 31.
Article in English | MEDLINE | ID: mdl-22057990

ABSTRACT

Tissue factor (coagulation factor III) is a cell surface receptor for coagulation factor VII/VIIa; it was initially recognized as an initiator of the extrinsic coagulation pathway. Recently, the zebrafish tissue factor gene (TF) has been cloned. Paralogs encode coagulation factors IIIa and IIIb; both show remarkable sequence identity to the human and mouse coagulation factor III gene. It has been reported that TF could have additional properties that are essential for normal embryonic development, since knockout of the murine coagulation factor III gene resulted in 90% embryonic lethality. We examined the role of coagulation factor IIIb (f3b) during zebrafish embryonic development. Expression analysis revealed that endogenous f3b was chronologically expressed in the pectoral fins and in the vicinity of the pharynx. Knockout of f3b by injection of an f3b morpholino at the one-to-two cell stage caused distinctive morphological defects in embryos, including edema in the fourth brain ventricle at early embryonic stages and occasional bleeding at later stages. Furthermore, f3b morphants displayed abnormal vascular patterning. We conclude that f3b is required for brain vascular development and for development of part of the somatic vasculature during embryogenesis in the zebrafish.


Subject(s)
Embryo, Nonmammalian/blood supply , Factor XIII/metabolism , Thromboplastin/metabolism , Zebrafish Proteins/metabolism , Zebrafish/embryology , Zebrafish/metabolism , Animals , Blood Coagulation/physiology , Embryo, Nonmammalian/metabolism , Factor XIII/genetics , Gene Knockout Techniques , Neovascularization, Pathologic/metabolism , Phenotype , Thromboplastin/genetics , Zebrafish Proteins/genetics
10.
Haemophilia ; 11(1): 31-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15660986

ABSTRACT

Factor X (FX) deficiency is a rare bleeding disorder inherited as an autosomal recessive trait. In this study, we investigated the molecular basis of FX deficiency in a Chinese pedigree. The proposita showed a markedly prolonged activated partial thromboplastin time and a mild prolongation of prothrombin time. The levels of FX antigen and FX activity were 58.6% and 2.5%, respectively. Molecular analysis revealed that the proposita was compound heterozygous for two novel mutations: IVS1 + 1G > A and G1185A (Arg347His). The aberrant transcripts from the IVS1 + 1G > A mutant allele were not detected by analyzing the splicing pattern of ectopic transcripts in leukocytes of the patient with nested polymerase chain reaction after reverse transcription. We thus hypothesize that the mRNA molecules originating from the IVS1 + 1G > A mutation were rapidly destroyed in vivo. Site-directed mutagenesis of FX cDNA was used to introduce FXG1185A mutation, and wild-type as well as mutant FX proteins were expressed by transient transfection in HEK 293 cells. Normal FX antigen levels both in the conditioned media of cells expressing the mutant and in cell lysates were detected by an enzyme-linked immunoadsorbent assay. Evaluation of wild-type and mutant coagulant activity demonstrated that the FX molecules carrying the Arg347His mutation have dramatically decreased activity.


Subject(s)
Factor X Deficiency/genetics , Factor X/genetics , Genes, Recessive , Mutation , Adolescent , Alternative Splicing , Animals , Autoantigens/blood , Cell Line , China , Cricetinae , Factor X/immunology , Factor X Deficiency/blood , Factor X Deficiency/immunology , Female , Heterozygote , Humans , Mutagenesis, Site-Directed , Partial Thromboplastin Time , Reverse Transcriptase Polymerase Chain Reaction , Transfection/methods
11.
Chemosphere ; 55(9): 1207-12, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15081761

ABSTRACT

Using a Fe/Cu bimetallic system (Fe/Cu system), the discoloration of both methylene blue in aqueous solution and the colored wastewater from a plant was investigated under the anaerobic condition in batch or continuous reactors. Results show that the Fe/Cu system effectively removed the color with over 88% of color removal efficiency for both methylene blue solution and the wastewater from the plant in batch test. Color removal efficiencies increased rapidly with Fe/Cu dosage and reaction time, respectively, at initial time and slowly to stable values. Optimum pH was neutral range. In addition, in continuous test it also removed the color of the wastewater from the plant with 63% of discoloring efficiency under the condition of 2 h of hydraulic retention time and neutral range of pH (7.0-8.3). High discoloring efficiencies with low chemical oxygen demand removal efficiencies were found in all experiments. The reduction of chromophores in pollutants was the main mechanism of the discoloration in the Fe/Cu system.


Subject(s)
Copper/chemistry , Iron/chemistry , Methylene Blue/chemistry , Waste Disposal, Fluid/methods , Water Pollutants, Chemical/analysis , Color , Hydrogen-Ion Concentration , Kinetics
12.
Haemophilia ; 10(3): 264-70, 2004 May.
Article in English | MEDLINE | ID: mdl-15086325

ABSTRACT

To investigate the molecular defects in two Chinese pedigrees with inherited factor V (FV) deficiency. A 37-year-old male (proband 1) and an 18-month-old boy (proband 2) were diagnosed as inherited coagulation FV deficiency by severely reduced plasma levels of FV activity and antigen. All 25 exons and their flanking sequence of F5 gene were amplified by polymerase chain reaction (PCR) for both probands and the PCR products were directly sequenced. Total RNA was extracted from the peripheral lymphocytes of proband 1 for detecting the changes at mRNA level. The homozygous deletion IVS8 -2A>G was identified in the F5 gene of proband 1 and complementary DNA (cDNA) analysis revealed the abolishment of the canonical splicing site by the mutation and the activation of the cryptic acceptor site 24 bp upstream instead. The insertion introduced eight additional amino acids (AA) into the FV protein. Two heterozygous mutations of F5 gene were discovered in proband 2. The 2238-9del AG in exon 13 introduced a premature termination code at 689 AA and the substitution of G6410 by T in exon 23 lead to the missense mutation Gly2079Val. Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with congenital FV deficiency, respectively.


Subject(s)
Factor V Deficiency/genetics , Factor V/genetics , Mutation/genetics , Adult , DNA/genetics , Factor V/analysis , Female , Humans , Male , Pedigree , Phenotype , Polymorphism, Genetic , Polymorphism, Restriction Fragment Length , Sequence Analysis, DNA
13.
Article in Chinese | MEDLINE | ID: mdl-8143197

ABSTRACT

Hemangioma is a common disease in infancy and childhood. From January, 1987 to January, 1992, the author had treated 11 out-patients of infants and children suffering from hemangioma with local injections of corticosteroid hormone and obtained an effective rate of 87.8% and cure rate of 51.2%. During the clinical observation, the author found that after injection, the hemangioma disappeared quickly without recurrence, infection, drug-induced side effects and other complications. It is considered that a mixture of corticosteroids is the first choice for local injection for the treatment of hemangioma in infancy and childhood. It is safe, effective and simple.


Subject(s)
Dexamethasone/administration & dosage , Hemangioma/drug therapy , Skin Neoplasms/drug therapy , Child, Preschool , Female , Humans , Infant , Injections, Intralesional , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...